T cell-mediated destruction of the myelin sheath causes inflammatory damage of the CNS in multiple sclerosis (MS). The major T and B cell responses in MS patients who are HLA-DR2 (about two-thirds of MS patients) react to a region between residues 84 and 103 of myelin basic protein (1). The crystal structure of HLA-DR2 complexed with myelin basic protein 84 -102 confirmed that Lys 91 is the major TCR contact site, whereas Phe 90 is a major anchor to MHC and binds the hydrophobic P4 pocket (2). We have tested peptides containing repetitive 4-aa sequences designed to bind critical MHC pockets and to interfere with T cell activation. One such sequence, EYYKEYYKEYYK, ameliorates experimental autoimmune encephalomyelitis in Lewis rats, an animal model of MS.
T he T cell recognition of myelin peptides embedded in MHC class II mediates the autoimmune attack in the human disease multiple sclerosis (MS) 4 (1). In MS patients, immune responses are detected against various components of the myelin sheath. Many of these myelin components can also induce experimental autoimmune encephalomyelitis (EAE), an animal model of MS (1) . Amino acids 85-99 of myelin basic protein (MBP) contain the immunodominant epitope for T cells and autoantibodies in MS brain lesions (3) (4) (5) (6) . The core motif from MBP peptide (MBPp) [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] , HFFK, is the predominant epitope recognized by T cells and autoantibodies in the brain of MS patients who are HLA-DRB1*1501 DQB1*0602 (HLA-DR2) (6) . In the Lewis rat, MBPp 85-99 induces EAE in a monophasic, self-limiting form. Acute paralysis lasts for a few days, followed by near total clinical recovery. In the Lewis rat model of EAE, the encephalogenicity of MBPp 85-99 is restricted by the RT1.D l MHC class II allele (DR like) (7) .
Previously, we compared the structural requirements for autoantibody recognition to those of T cell clones reactive to MBPp 85-99 in humans. Anti-MBP Abs were affinity-purified from CNS lesions of 12 postmortem cases studied. The MBPp 87-99 was immunodominant in all cases and inhibited Ab binding to MBP by Ͼ95% (6) . Ab-binding residues were located in a 10-aa segment at position 86 -95 (VVHFFKNIVT) that contained the MHC-TCR contact residues for T cells recognizing MBP in the context of DRB1*1501 and DQB1*0602. In the epitope center, the same residues (VHFFK) were important for T cell binding and MHC recognition (6) .
The crystal structure of HLA-DR2 with MBPp 85-99 confirmed that Phe 90 is a major anchor for the hydrophobic P4 pocket of the MHC molecule, whereas Lys 91 is the major TCR contact residue (2) . Substitution at Lys 91 creates an altered peptide ligand (APL) that can reverse paralysis and reduce proinflammatory cytokine production in the Lewis rat (8) . One such APL, MBPp 87-99 (Lys 91 -Ala), neither binds anti-MBP Abs nor triggers MBP-specific T cells. The characteristics of this molecule have guided APL clinical trials for therapy in MS patients (9) . The search for optimal APLs can provide new therapeutic tools in the treatment of autoimmune diseases.
We have designed peptides containing repetitive amino acid sequences that, according to computer modeling, bind the pockets of MS-related MHC molecules and potentially interfere with the activation of pathogenic T cells. These peptides incorporate the four amino acids, glutamate, tyrosine, lysine, and alanine, used to create the random copolymer, glatiramer acetate (GA). GA, known as Copaxone, is currently approved for the treatment of MS. The molar ratio of Ala:Lys:Glu:Tyr in GA is 4.5: 3.6:1.5:1, respectively; the copolymer has an average length of 40 -100 aa. The ratio of these four amino acids was chosen to reflect their relative composition in MBP. Directly labeled GA efficiently binds to different murine and human MHC class II molecules (10, 11) .
We report here that one possible sequence from these four amino acids, EYYKEYYKEYYK, is effective in preventing and treating EAE in the Lewis rat, an animal model of MS. It may thus be possible to simplify and define the active components of a random copolymer like GA. We have designed an APL based on computer modeling. This strategy, designing molecules based on their predicted capacity to bind MHC class II, may prove effective for the design of other molecules useful for intervention in a variety of immune-related diseases.
Materials and Methods

Animals
Female Lewis rats (6 -8 
Peptide-MHC binding assay
Peptide binding to class II molecules was measured as described before (8) with some modifications. Briefly, APCs were purified from spleen cells by negative selection using magnetic beads (Dynal, Oslo, Norway) conjugated with Abs specific for T cells (CD52), macrophages (HIS36), and NK cells (NKR-P1A) (BD PharMingen, San Diego, CA). After selection, cells were plated at a concentration of 0.5 ϫ 10 6 cells/well in flat-bottom 96-well microtiter plates (Corning Costar, Corning, NY). EYYK and KYY peptides were added to the wells at different concentrations (ranging from 0.01 to 0.24 mM) in a volume of 0.05 ml. After 1 h of incubation at 37°C, 0.01 mM biotinylated MBPp 85-99 was added. After 4 h more of incubation, cells were harvested, and binding of PE-avidin to the cell surface was analyzed by FACS (BD Biosciences, San Jose, CA). To determine the IC 50 value of EYYK, a linear regression curve was calculated using data points from 0.01 to 0.80 mM. Additional data points were not included because the reaction saturated at concentrations above 80 M.
Computer modeling
The structural modeling of the peptide-MHC complexes was performed using Insight II (Accelerys, San Diego, CA). The crystal structure of HLA-DR2 complexed with a peptide from human MBP (2) was used as a template for all studies. Substitutions in the native MBP sequence were done using the residue replace function of InsightII. The backbone and side chain torsion angles of the original residues were retained. Steric clashes and chemical incompatibilities were assessed manually. A RasMol-readable script was then exported from InsightII and imported into RasMol for rapid imaging.
Alignment of human and rat MHC class II
Homology analysis was done using ClustalW with a Blosum matrix (12) . The protein sequences are identified in GenBank as: 60497 for RT1.D l and 1BX2B for HLA-DR2. The ClustalW output was formatted in BoxShade for presentation.
EAE induction
Guinea pig spinal cord homogenate (gpSCH) or synthetic MBPp 85-99 was dissolved in 1 M PBS to a final concentration of 5 mg/ml or 2 mg/ml, respectively, and emulsified with an equal volume of IFA supplemented with 4 mg/ml heat-killed Mycobacterium tuberculosis H37Ra (Difco, Detroit, MI). Rats were injected s.c. with 0.1 ml of the peptide emulsion. Experimental animals were assessed for signs of clinical disease as follows: 0, no clinical disease; 1, tail weakness or paralysis; 2, hind limb weakness; 3, hind limb paralysis; 4, forelimb weakness or paralysis; and 5, moribund or dead animal.
Peptide treatment
For disease prevention, peptides were emulsified in IFA to a final concentration of 1 mg/ml. A total of 0.1 ml was injected intradermally, once on day Ϫ20 and again on day Ϫ10. Animals were challenged for EAE with gpSCH at day 0. For treatment of ongoing disease, EAE was induced with a 0.1-mg emulsion of MBPp 85-99 in CFA. On the first day of acute clinical disease, rats were injected i.p. with a dose of 0.5 mg peptide (EYYK or KYY) in 1 ml 1 M PBS.
Results
The ordered peptide EYYKEYYKEYYK inhibits MBPp 85-99 binding to rat MHC class II molecules
A competition assay was performed to test whether the ordered peptide EYYK inhibits the binding of MPB 85-99 to the MHC class II molecule. The ordered peptides EYYK and KYY were incubated with APCs and allowed to bind the MHC cleft. After 1 h of incubation, biotinylated MBPp 85-99 was added and incubated for 4 h more. The APCs were analyzed by flow cytometry to determine the amount of biotinylated MBPp 85-99 bound to MHC class II. As shown in Fig. 1 (Fig. 2 ). Although energy minimization or interatomic contacts were not calculated, obvious steric clashes and chemical incompatibilities were avoided.
In our model, residues 90, 91, and 93 project out of the cleft and are implicated in TCR recognition. The glutamate that replaces His 90 carries a negative charge and may block TCR signaling by electrostatic repulsion. The addition of a polar hydroxyl group onto a hydrophobic TCR contact residue (Phe 91 3 Tyr) could also be deleterious to TCR engagement. In our model, the Phe 92 3 Tyr change results in the submersion of the aromatic ring into the cleft (Fig. 3) . In the native peptide, Phe 92 is important in anchoring the peptide to the P4 hydrophobic pocket of the MHC class II molecule (2). However, the P4 pocket is not entirely hydrophobic, and several residues could form hydrophilic interactions with the polar tyrosine hydroxyl of EYYK. Hydrophilic residues that could potentially form hydrogen bonds with tyrosine in the EYYK peptide are shown in Fig. 4 . These residues may stabilize the binding of EYYK in the MHC cleft, helping it block native MBPp 85-99 .
The residues derived from the crystal structure are based on a human HLA-DR molecule (2). Because we conducted our experiments in Lewis rats and the residues are not identical, we tested the homology of the two sequences. The rat (RT1-D l ) and human MHC class II (DRB1*1501) molecules were aligned and analyzed to determine whether peptide-MHC interactions are conserved. The result of this alignment is shown in Fig. 5 . In humans, the In rats, these residues are Gly, Leu, Ala, Gln, Leu, and Ala, respectively. The presence of the large aromatic residues in the human molecule may decrease the size of the P4 pocket. However, the HLA-DR2 P4 pocket can accommodate a phenylalanine residue, so size is most likely not a factor. Based on our modeling, the hydrophilic residues in the predominantly hydrophobic P4 binding pocket may anchor EYYK to the MHC. Hydrophilic residues that could stabilize EYYK in the MHC cleft are found in both molecules. The crystal structure of HLA-DR2 with MBPp [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] showed that Gln 70 is positioned over the P4 pocket (2) . Gln 70 is conserved in RT1.D l , making it capable of hydrophilic interactions with EYYK.
The EYYK ordered peptide inhibits the development of EAE
We tested the potential of the predicted peptide sequences to prevent or to revert the development of EAE in Lewis rats. Induction of EAE in Lewis rats can be achieved by immunization with SCH, whole MBP, or MBPps. Responses to MBPp 68 -88 are restricted by the RT1.B MHC class II allele, and responses to MBPp 85-99 are restricted by the RT1.D allele (13) . It has been demonstrated that autoimmune responses to Ags containing more than one pathogenic epitope can be controlled by the previous exposure of the immune system to an APL derived from one of those epitopes (14, 15) . To measure the degree of immunomodulation by the ordered peptide EYYK on EAE induced by gpSCH known to contain the dominant epitope MBPp 72-88 , the experimental animals were injected on days 0 and 10 intradermally with a 0.1-ml emulsion of 0.1 mg ordered peptide in IFA. Ten days after the last injection, rats were immunized with an emulsion of 0.5 mg gpSCH in CFA. As seen in Fig. 6 , injection of EYYK in IFA has a protective effect when EAE is induced with an emulsion of gpSCH and CFA, as compared with animals immunized with KYY peptide or IFA alone ( p ϭ 0.052). We then tested whether this inhibition was specific for a blockade of anti-MBPp 85-99 responses. In MBPp 85-99 -immunized Lewis rats, we delivered a single dose of EYYK (a solution of 0.5 mg peptide in 1 ml 1 M PBS i.p.) on the day when the first signs of clinical disease became apparent. As seen in Fig. 7 , administration of EYYK suppresses the development of clinical disease in experimental animals when compared with KYY-or PBS-treated animals.
Discussion
In this report, we used MHC class II binding motifs of MBP to design optimized analogs containing repetitive peptide sequences that prevent and suppress EAE in Lewis rats.
One currently approved drug for MS therapy is a random synthetic amino acid copolymer, GA (poly Tyr, Glu, Ala, and Lys) (16) . Glatiramer suppresses EAE in rodents, slows the progression of disability, and reduces the relapse rate in MS. The mechanism of action is likely MHC blocking and TCR antagonism of MBPp 82-100 -specific T cells (16) . Binding-motif analyses of glatiramer after elution from HLA-DR molecules showed tyrosine at the first anchor position followed by alanine in the subsequent pockets (17) . Although glatiramer is a random sequence of amino acids and each batch has considerable variability, Fridkis-Hareli et al. (17) have suggested that substitutions of valine or phenylalanine for tyrosine may improve glatiramer's efficacy for binding to the P1 pocket of HLA molecules.
APLs, in contrast to glatiramer, have a defined sequence and change autoimmune responses in part by altering cytokine production in autoreactive T cells (18 -20) . Previously, an APL of MBPp 85-99 was designed based on TCR-MHC contact residues (21) . Administration of MBPp 87-99 (Lys 91 3 Ala), an APL in which the primary TCR contact residue is changed, reversed EAE induced paralysis in the Lewis rat and reduced production of the proinflammatory cytokine TNF-␣ (8) . In a recent report, the minimal structural requirements for a peptide to tolerize animals with ongoing EAE were determined (22) . Using a panel of truncated variants of the MBPp 87-99 , a 7-aa peptide, FKNIVPT, was found to induce remission of EAE in the Lewis rat model. These results indicate that only one MHC anchor and one TCR binding site are essential for initiation of Ag-specific T cell tolerance (22) . However, these peptides closely resemble the original self peptide and have the potential to induce cross-reactive adverse side effects when used for therapeutic purposes.
The peptides we designed contain repetitive sequences of three (KYY) or four (EYYK and AYEK) amino acids and resemble the Previously, MBPp 86 -100 was oligomerized into a 16-mer. This oligomerized peptide treated ongoing disease and prevented disease when administered before EAE induction. Interestingly, the peptide also induced EAE in traditionally "resistant" strains (23) . In this study, we have minimized the number of amino acids required to treat and prevent disease. In addition, we have created a peptide that is not homologous to MBP and does not induce EAE or cause B or T cell cross-reactivity to MBP (data not shown). EYYK and AYEK are tetrad repeats, similar to the native HFFK structure. AYEK, a similar tetrad structure, resulted in partial abrogation of EAE (data not shown). Unlike AYEK or EYYK, KYY is a triplet repeat and contains fewer HFFK-analogous binding regions (Fig. 8) . KYY did not bind MHC or prevent disease. This observation suggests that there is a minimum of four residues per repeat required for efficient APL binding.
The oligomerized MBPp 86 -100 improved the response of low avidity T cell clones (23) . The repetitive structure may effectively raise the local concentration of peptide. If the tyrosine residues of EYYK are structurally predisposed to bind in pockets P3 and P4 of the rat MHC class II, then EYYK contains three potential binding regions (the first, second, and third repeat of EYYK). When EYYK binds and then releases from the MHC cleft, two other EYYK binding regions are immediately adjacent and can bind the MHC molecule (Fig. 8) . This would give the peptide a fast on/off rate and a high avidity for binding.
Further studies should be conducted to determine the importance of the first amino acid of the repeat in abrogating EAE. In the native HFFK sequence, histidine is first and carries a positive charge (His  90 ) . KYY, which starts with another positively charged amino acid, resulted in a slight increase in EAE scores. Electrostatic interactions between His 90 and TCR residues may trigger a nontolerogenic signal. Altering the charge of this residue can affect the stimulatory capacity; when converted to a nonpolar alanine (AYEK), partial abrogation of EAE is observed. Furthermore, when changed to the negatively charged amino acid glutamate (EYYK), there is a significant reduction in EAE scores.
The P4 pocket is a major anchor for the peptide to the MHC cleft. Although the residues that make up the cleft differ between human and rat MHC, the crystal structure of human HLA-DR2 suggests that tyrosine can act as an anchor residue in the P4 pocket (2) . The polar end group of tyrosine potentially interacts with Gln 71 , a residue positioned over the P4 pocket in human and rat MHC. The EYYK peptide was designed with the structure of rat RT1.D l in mind, where the P4 pocket is composed of mainly nonpolar residues that could interact with the aromatic portion of tyrosine. In humans, the P4 pocket consists of multiple polar and charged residues. Despite structural studies suggesting that tyrosine will fit in the human P4 pocket, peptides designed for human use could be engineered with a polar residue. MBP analogs that contain histidine, arginine, lysine, glutamine, or asparagine instead of Phe 92 bind the P4 pocket (2, 4). The possibility of using crystal structures of HLA molecules to design TCR-MHC antagonists should improve the pace of discovery for new therapies in autoimmune diseases. As the interactions between MHC, peptide, and TCR are defined, disease-and genotype-specific APLs will become possible.
